Thursday, April 16, 2015 11:04:00 AM
An Odd Couple's Corporate Fix for Cancer
EU certified organic farm-raised shrimp are for sale on at the Wegmans, Friday, April 10, 2015 in Fairfax, Va. Organic fish is certified in the EU and Canada because the US doesn’t have any standard.
USDA to propose standards for organic seafood raised in US
?
Cary Chin works Wednesday, April 15, 2015, at the front desk of Gravity Payments, a credit card payment processor based in Seattle. Gravity CEO Dan Price told his employees this week that he was cutting his roughly $1 million salary and using company profits so they would each earn a base salary of $70,000, to be phased in over three years.
Seattle CEO to cut his pay so every worker earns $70,000
Sixty-eight years is a long time to spend thinking about something as depressing as cancer. But that’s how long 71-year-old Dr. Charles Wiseman has had it on his mind. After losing his father to leukemia at the age of 3, Wiseman “was pissed.” Even as a toddler.
Weaving his way through Los Angeles traffic on a sunny Wednesday afternoon, he admits, “It’s a little harder than I thought it was when I was 10.”
Certainly the words “celebrity” and “cancer” are not entirely unfamiliar bedfellows. But more often than not the two combine to refer to a star stepping into activism. Wiseman is another sort, a celebrity cancer doctor. Movie stars, foreign dignitaries and the wealthy elite come to him for treatment. And for good reason: He is known for being part of the team at Houston’s MD Anderson Cancer Center that pioneered chemotherapy, the most common method today for battling cancer. He was also one of the first oncologists to start developing breast cancer vaccines, before the term “cancer vaccine” was even being used. For 45 years, Wiseman has worked as the principal investigator on innovative treatment protocols at St. Vincent’s Cancer Treatment Center and the Los Angeles Oncologic Institute. He’s the author of more than 100 medical papers. And today, he may be closer than ever to breaking through on that long-ago promise he made to his childhood self.
Silver-haired and sporting 1980s-esque glasses, Wiseman continues to chase success, this time by way of a promising vaccine. Perhaps most interesting, he’s betting on that vaccine to take off thanks to a corporation — one that’s on the map only because of a 24-year-old former investment banker turned partner he met at a wedding.
The vaccine is an experimental treatment called BriaVax. In the United States under FDA rules, experimental cancer treatments like Wiseman’s can be tested only on patients with late-stage cancer who have failed every other possible treatment option. Nearly 12 years ago, Wiseman gathered some cancer cells from a patient because they were uniquely easy to work with, and re-engineered them to break down the tolerance cancers often have toward the immune system. The first safety trial in 2006 doubled the patients’ expected lifetime for a median span of 12 months. “We didn’t know if that was a flash in the pan, or something real,” he reflects. “But by God, we better figure out what Mother Nature is trying to tell us.”
But Wiseman’s work was put on hold in 2006. The program lost financial support from the hospital, and after the recession, other funding sources dried up. He was crestfallen, but decided to dedicate much of his retirement savings to keeping the project alive — “I wouldn’t be able to face my maker if I wasn’t able to say I tried everything possible,” he says today. All this while running his own private practice. Even his purse couldn’t last forever, though. Enter Isaac Maresky, a then 22-year-old investment banker from Toronto, who helped produce a solution: a company called BriaCell, over whose board he would preside. They’d escape the tribulations of the limiting research-funding world.
This is a rare strategy in the land of medical research. Most U.S.-based companies with only a single product in the trial phases seek private angel or venture-capital investment, says William Phelps, the director of preclinical and translational cancer research at the American Cancer Society. Maresky, however, coolly took the company public in December 2014, raising just over $3 million; it was listed on the Toronto Stock Exchange at 18 cents per share. In a world of serious funding cuts from the National Institutes of Health — a 2013 sequestration by the Obama administration required a 5 percent cut of NIH’s budget, contributing to an overall budget reduction of 25 percent since 2003 — more medical research needs to be funded from more creative sources. Could Wiseman and Maresky have the fix?
Perhaps for a short while. Without a product on the horizon to sell — e.g., the actual BriaVax vaccine — the company has zero revenue, just investment. (Maresky isn’t too concerned; he says the evidence thus far already has investors in a tizzy.) And there are the usual medical caveats: The vaccine has been used to treat only breast cancer so far, and while the results have been impressive, there is no telling how it will fare against other forms of cancer.Wiseman believes he will likely have to wait two or three years before the drug is fully approved by the FDA for nonexperimental use, but according to Phelps, the trial process typically takes nearly double that much time. (The FDA says it cannot comment on drugs currently in experimental trials.)
Further safety trials of four late-stage breast cancer patients with the BriaVax vaccine concluded in 2008. These were patients who had run out of options, whose immune systems were failing, with a timeline of three to seven months to live. They survived a median of 35 months, roughly five times longer than expected.
One of the patients saw her breast cancer regressed by 90 percent, and virtually disappeared in a lung lesion. But after the FDA-approved trial period of five months, the patient’s cancer returned and spread throughout the breast, lungs and even into the brain. Once BriaCell secured permission from the FDA to provide the patient with additional treatments of the vaccine three months later, however, all cancers regressed rapidly, some entirely, and without side effects.
In March, Wiseman and Co. are seeking FDA permission to test another 24 patients — this time, those with prostate, ovarian, pancreatic, lung, bladder and other cancer types. It’s the biggest test the drug has faced yet. With a long road ahead, this near 80-year-old doctor, who might have long ago retired, has no intention of trading in his lab coat for golf clubs anytime soon.
Recent BCTX News
- BriaCell Announces Oral and Poster Presentations at ASCO 2024 • GlobeNewswire Inc. • 04/24/2024 12:00:33 PM
- BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer • GlobeNewswire Inc. • 04/10/2024 12:00:00 PM
- BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR • GlobeNewswire Inc. • 04/09/2024 12:00:00 PM
- BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies • GlobeNewswire Inc. • 03/07/2024 01:00:00 PM
- BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference • GlobeNewswire Inc. • 03/06/2024 01:00:26 PM
- BriaCell Provides Update on Alleged Illegal Trading of Public Securities • GlobeNewswire Inc. • 02/27/2024 01:00:00 PM
- BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case • GlobeNewswire Inc. • 02/07/2024 01:00:37 PM
- Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing • GlobeNewswire Inc. • 02/06/2024 01:30:53 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/01/2024 05:15:24 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 10:24:58 PM
- BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting • GlobeNewswire Inc. • 01/31/2024 03:48:36 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/22/2024 10:00:49 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/09/2024 09:05:36 PM
- BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer • GlobeNewswire Inc. • 01/04/2024 01:45:00 PM
- BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients • GlobeNewswire Inc. • 12/28/2023 01:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:38 PM
- BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset • GlobeNewswire Inc. • 12/20/2023 01:40:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/14/2023 10:00:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/14/2023 10:00:35 PM
- BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS • GlobeNewswire Inc. • 12/06/2023 02:31:11 PM
- BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit • GlobeNewswire Inc. • 12/06/2023 02:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/30/2023 12:00:38 PM
- BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor • GlobeNewswire Inc. • 11/30/2023 12:00:00 PM
- BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND • GlobeNewswire Inc. • 11/03/2023 12:31:01 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM